Dicerna Pharmaceuticals (NASDAQ:DRNA) Lowered to “Hold” at ValuEngine

ValuEngine lowered shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) from a buy rating to a hold rating in a research report report published on Tuesday morning, ValuEngine reports.

DRNA has been the subject of a number of other research reports. HC Wainwright reiterated a buy rating and issued a $30.00 target price (up previously from $22.00) on shares of Dicerna Pharmaceuticals in a research report on Tuesday, November 19th. Cowen reissued a buy rating on shares of Dicerna Pharmaceuticals in a research note on Monday, November 18th. Zacks Investment Research upgraded shares of Dicerna Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, November 5th. BidaskClub raised shares of Dicerna Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Saturday, November 9th. Finally, Leerink Swann reiterated an outperform rating and set a $30.00 price objective (up from $26.00) on shares of Dicerna Pharmaceuticals in a report on Tuesday, November 19th. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $27.38.

Shares of DRNA opened at $25.89 on Tuesday. The business’s 50-day moving average is $19.15 and its 200-day moving average is $15.37. The company has a market capitalization of $1.65 billion, a price-to-earnings ratio of -21.57 and a beta of 2.38. Dicerna Pharmaceuticals has a fifty-two week low of $9.31 and a fifty-two week high of $26.69.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.15). Dicerna Pharmaceuticals had a negative return on equity of 58.92% and a negative net margin of 541.24%. The company had revenue of $8.04 million for the quarter, compared to analyst estimates of $11.70 million. On average, equities analysts predict that Dicerna Pharmaceuticals will post -1.28 earnings per share for the current year.

In other news, major shareholder Bain Capital Life Sciences Inv sold 1,750,000 shares of the firm’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $22.03, for a total transaction of $38,552,500.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO John B. Green sold 12,500 shares of Dicerna Pharmaceuticals stock in a transaction on Thursday, October 31st. The shares were sold at an average price of $18.00, for a total transaction of $225,000.00. The disclosure for this sale can be found here. In the last three months, insiders sold 3,619,826 shares of company stock valued at $82,994,979. 21.28% of the stock is currently owned by company insiders.

Institutional investors have recently bought and sold shares of the business. Metropolitan Life Insurance Co NY raised its holdings in Dicerna Pharmaceuticals by 5.1% during the third quarter. Metropolitan Life Insurance Co NY now owns 18,110 shares of the biopharmaceutical company’s stock valued at $260,000 after buying an additional 879 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Dicerna Pharmaceuticals by 1,433.5% during the 3rd quarter. Millennium Management LLC now owns 375,640 shares of the biopharmaceutical company’s stock worth $5,394,000 after acquiring an additional 351,145 shares in the last quarter. Squarepoint Ops LLC increased its holdings in shares of Dicerna Pharmaceuticals by 76.5% during the 3rd quarter. Squarepoint Ops LLC now owns 42,976 shares of the biopharmaceutical company’s stock valued at $617,000 after acquiring an additional 18,623 shares during the last quarter. California State Teachers Retirement System increased its holdings in shares of Dicerna Pharmaceuticals by 1.2% during the 3rd quarter. California State Teachers Retirement System now owns 80,679 shares of the biopharmaceutical company’s stock valued at $1,159,000 after acquiring an additional 964 shares during the last quarter. Finally, Carillon Tower Advisers Inc. acquired a new position in shares of Dicerna Pharmaceuticals during the 3rd quarter valued at about $16,088,000. 84.77% of the stock is currently owned by hedge funds and other institutional investors.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Featured Story: What Are Cryptocurrencies?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.